ADCs Continue to Make First-Line Inroads in Triple-Negative Breast Cancer

(MedPage Today) — Antibody-drug conjugates (ADCs) are becoming an increasingly relevant first-line treatment option for metastatic triple-negative breast cancer (TNBC). "ADCs are a fairly old class of drug that has really transformed the treatment…

Source: MedPage Today — Headlines